Clemizole HCl

Phase 3Small molecule

EEpygenix

Clemizole HCl is one of 20 small molecule programs targeting Lennox-Gastaut syndrome. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lennox-Gastaut SyndromeActive, not recruiting

Dravet SyndromeActive, not recruiting

Lennox-Gastaut SyndromePhase 3

Active, not recruiting

Dravet SyndromePhase 3

Active, not recruiting

Competition

Competitive Landscape

16 competitors in Dravet Syndrome

#DrugCompanyPhaseTrials

Epidiolex

Jazz Pharmaceuticals

Phase 3

2 2

Sympazan

Lundbeck

Phase 3

2 3

Lorcaserin

Eisai

Phase 3

2 4

Soticlestat

Takeda

Phase 3

1 5

Translarna

PPTC Therapeutics

Phase 2

1 6

Calan

VVal Adams

Phase 2

1 7

GWP42003-P

Jazz Pharmaceuticals

Phase 2

3 8

Clemizole HCl

EEpygenix

Phase 3

1 9

LP352

LLongboard Pharmaceuticals

Phase 3

1 10

Zorevunersen

SStoke Therapeutics, Inc

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

Phase 3Recruiting

Dravet Syndrome

NCT04462770

Q4 2029

Phase 3Recruiting

Lennox-Gastaut Syndrome

NCT05066217

Clinical

Trials by Indication[1]

Lennox-Gastaut syndrome1 trial

Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Clemizole HCl as Adjunctive Therapy in Patients With Lennox-Gastaut Syndrome

Recruiting·EEpygenix·Phase 3·NCT05066217·260 enrolled

Dravet syndrome1 trial

A 20-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of EPX-100 (Clemizole Hydrochloride) as Adjunctive Therapy in Children and Adult Participants With Dravet Syndrome (ARGUS Trial)

Recruiting·EEpygenix·Phase 3·NCT04462770·150 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Clemizole HCl. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Clemizole HCl compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Clemizole HCl. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Epygenix company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: EEpygenix

Clemizole HCl

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2029

Q4 2029

Trials by Indication[1]

Lennox-Gastaut syndrome1 trial

Dravet syndrome1 trial

References

Drug Info

Quick Facts

Related News